Search

Your search keyword '"Romero-Gomez, Manuel"' showing total 700 results

Search Constraints

Start Over You searched for: Author "Romero-Gomez, Manuel" Remove constraint Author: "Romero-Gomez, Manuel"
700 results on '"Romero-Gomez, Manuel"'

Search Results

1. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

2. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

3. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

4. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

5. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

6. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

11. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

14. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

15. Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

17. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

18. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding

20. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

21. A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.

22. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

23. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease

24. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

26. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

27. Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and expanding A. muciniphila

28. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

29. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis

30. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

31. A global research priority agenda to advance public health responses to fatty liver disease

32. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography

33. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

34. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

35. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

36. Research Priorities for Precision Medicine in NAFLD

37. Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease

39. Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas»

40. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials

41. FRI-501 Platelet-derived extracellular vesicles (PEVs) as a potential biomarker for hepatocellular carcinoma (HCC)

42. THU-268 Differential transcriptomic profile in platelet-derived extracellular vesicles in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

43. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis

45. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry

48. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

49. Hepatic encephalopathy

Catalog

Books, media, physical & digital resources